Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.45 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914426 | 0.93 | SLC2A1 (0.40) | CHRM1SLC2A1DRD2DRD4GAA | |
| SCHEMBL3440718 | 0.91 | CHRM1 (0.48) | CHRM1GAAMAPTLMNARAB9A | |
| SCHEMBL13017270 | 0.89 | USP2 (0.43) | DRD2DRD4MAPTLMNAHTT | |
| SCHEMBL3439816 | 0.84 | MAPT (0.49) | GAAMAPTLMNARAB9AHTT | |
| SCHEMBL12914380 | 0.83 | HTT (0.46) | GAAMAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL3439743 | 0.82 | GAA (0.52) | GAAMAPTLMNARAB9AKDM4E | |
| SCHEMBL15372645 | 0.81 | MAPT (0.44) | DRD2DRD4GAAMAPTLMNA | |
| SCHEMBL3440068 | 0.80 | CHRM1 (0.48) | CHRM1DRD2DRD4GAAMAPT | |
| SCHEMBL3439976 | 0.80 | CHRM1 (0.47) | CHRM1DRD2DRD4MAPTF10 | |
| SCHEMBL3440719 | 0.80 | MT-CO2 (0.47) | GAAMAPTLMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2188251-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2061779-B1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INT (DE) | 2013-11-06 | — | — | EP | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| US-8450306-B2 | Bradykinin B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-28 | — | — | US | disclosed |
| EP-2402329-B1 | Analgetic phenylsulphonamides | BOEHRINGER INGELHEIM INT (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294775-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-7858618-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | CHRM1 97/4885SLC2A1 1711/4885DRD2 45/4885 |
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | CHRM1 53/4885SLC2A1 1919/4885DRD2 25/4885 |
| US-20110294775-A1 | NOVEL COMPOUNDS | TRPV1, OPRL1, TRPA1 | CHRM1 1115/4885SLC2A1 3081/4885DRD2 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.